0001193125-26-049031
SEC filingAVITA Medical, Inc. (RCEL) reported total revenues of $71.6M for the fiscal year ended December 31, 2025, generating a gross profit of $58.8M. Despite strong revenue generation, the company incurred significant operating expenses totaling $101.3M, driven primarily by sales and marketing costs of $53.1M, resulting in an operating loss of $42.5M and a net loss of $48.6M. The company reported a loss per share of $2.00. Financially, AVITA maintains a liquidity position of $18.1M in cash and marketable securities; however, the balance sheet reflects a stockholders' equity deficit of $16.6M and total liabilities of $73.0M against total assets of $56.4M. Cash flow from operations used $31.2M, offset by $14.9M in financing proceeds and $12.5M provided by investing activities. The company continues to fund operations through a mix of debt facilities and equity raises, evidenced by a $43.0M loan facility and recent private placement proceeds.
For the fiscal year ended December 31, 2025, AVITA Medical reported total revenues of $71.6M, comprised of $70.9M in sales revenue and $731K in lease revenue. The company achieved a gross profit of $58.8M, reflecting a robust gross margin. However, high operating costs led to substantial losses. Total operating expenses reached $101.3M, resulting in an operating loss of $42.5M. After accounting for $5.0M in interest expense and other costs, the net loss totaled $48.6M. This represents a basic and diluted net loss per share of $2.00, based on 27.9M weighted-average common shares outstanding.
Revenue was driven entirely by product sales and lease income, with sales revenue contributing the vast majority at $70.9M. The document does not provide a specific geographic or product segment breakdown, nor does it offer prior-year comparative figures to assess growth trends. The $731K in lease revenue suggests a secondary income stream, likely related to equipment placement or service agreements, but specific details regarding revenue drivers were not disclosed in the provided data.
The company demonstrated a strong gross margin of approximately 82.1% ($58.8M gross profit on $71.6M revenue), indicating effective production cost management relative to sales. However, profitability was heavily impacted by operating expenses. Sales and marketing alone consumed 74% of gross profit ($53.1M). Consequently, the operating margin stood at -59.4%. The net profit margin was -67.9%, exacerbated by $5.0M in interest expenses on the company's debt facilities.
The company's liquidity position includes $10.2M in cash and $7.9M in marketable securities, totaling $18.1M. Operating activities consumed $31.2M in cash. Investing activities provided $12.5M, largely from $27.5M in maturities of marketable securities. Financing activities provided $14.9M, primarily from a $14.8M private placement. The balance sheet shows a deficit in stockholders' equity of $16.6M, with total assets of $56.4M outweighed by total liabilities of $73.0M, which includes a $43.0M loan facility.
The filing indicates reliance on external financing to fund operations, evidenced by the recent private placement and existing loan facility. The accrued wages and contingent liabilities suggest ongoing operational commitments. Without explicit forward-looking guidance in the provided text, the focus remains on managing the cash burn rate ($31.2M used in operations) against the current liquidity runway and available credit facilities.